Doug Drysdale On How CYB-003 Is Better Than Psilocybin

MindMed (MMEDF/MMED) stock EXPLODED in the past week which raises the question: Is it too late to BUY MindMed stock? Watch the video as I provide my insight on some factors you might want to consider. 💯

Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.

ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.

The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.

This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.

In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.

To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/

#psychedelics #therapy #magicmushrooms